Coloplast A/S - Interim Financial Report, 9M 2025/26

Interim financial results, 9M 2025/26
1 October 2025 - 30 June 2026

Coloplast delivered Q3 organic growth of 6% and 5% EBIT growth¹ in constant currencies. Strong quarter in both Chronic Care ex. China and Interventional Urology; continued reimbursement-related challenges in Biologics. Reported revenue in DKK also grew 6%, as currencies had a net neutral impact. Return on invested capital after tax before special items was 15%.
• Organic growth rates by business area: Ostomy Care 5%, Continence Care 8%, Voice & Respiratory Care 6%, Wound & Tissue Repair 3%, and Interventional Urology 7%.
• Strong quarter in Ostomy Care ex. China, with strong double-digit growth in the US and solid performance in Europe and Emerging markets ex. China.
• Strong quarter in Continence Care, with double-digit growth in the US and solid growth in Europe, driven by Luja.
• Solid quarter in Voice & Respiratory Care, with strong growth in Laryngectomy and softer quarter in Tracheostomy.
• Challenging quarter in Biologics with 6% sales decline and -5% EBIT margin before PPA amortisation, due to the reimbursement change.
• Advanced Wound Dressings grew 4%: good momentum in the US and positive impact from phasing in Germany and the Middle East, partly offset by the China product return.
• Continued strong momentum in Interventional Urology, driven by the US Men’s Health business.
• EBIT^1,2 was DKK 1,929 million. EBIT^1,2 in constant currencies increased 5% compared to last year, while reported EBIT^1,2 increased 1% from last year. The EBIT margin^1,2 was 26%, against 28% last year, and includes around 110 basis points negative impact from currencies and around 60 basis points negative impact from Kerecis.